Drug Trial Radar · NCT06560489
Pharmacokinetics and Efficacy of Multiple Dosing of LP-98 for Injection in HIV-infected Patients
Last checked: Nov 19, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Sep 2, 2024
Primary completion
Jan 10, 2025
Study completion Aug 22, 2025
Sponsor
- Lead sponsor
- Shanxi Kangbao Biological Product Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Institute of Pathogen Biology, Beijing, China
- First posted
- Aug 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Randomized, Double-Blind, Parallel-Group, Exploratory Clinical Study to Evaluate the Safety, Pharmacodynamic Effects, and Pharmacokinetic Characteristics of Multiple Subcutaneous Injections of LP-98 in Treatment-Naive HIV-Infected Individuals
Conditions
- Hiv
Interventions
Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.Drug
This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes from baseline in respiration rate of Vital Signs.Time frame: Within 71 days after the first administration.
- Changes from baseline in blood pressure of Vital Signs.Time frame: Within 71 days after the first administration.
- Changes from baseline in Blood lactate of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in body temperature of Vital Signs.Time frame: Within 71 days after the first administration.
- Changes from baseline in red blood cell count of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in white blood cell count of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in neutrophil count of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in lymphocyte count of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in platelet count of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in hemoglobin of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in PT of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in INR of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in APTT of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in total bilirubin of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in direct bilirubin of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in ALT of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in AST of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in total protein of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in albumin of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in urea of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in creatinine of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in uric acid of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in glucose of Laboratory ExaminationTime frame: Within 71 days after the first administration.
- Changes from baseline in potassium of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in sodium of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in chlorine of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in urine specific gravity of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in urine pH of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in urine glucose of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in urine protein of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in urine ketone body of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in urine white blood cell of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in urine bilirubin of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in urine occult blood of Laboratory Examination.Time frame: Within 71 days after the first administration.
- Changes from baseline in Electrocardiogram.Time frame: Within 71 days after the first administration.
- Changes from baseline in CK of Laboratory ExaminationTime frame: Within 71 days after the first administration.
- Changes from baseline in CK-MB of Laboratory ExaminationTime frame: Within 71 days after the first administration.
- Changes from baseline in LDH of Laboratory ExaminationTime frame: Within 71 days after the first administration.
- Changes from baseline in ALP of Laboratory ExaminationTime frame: Within 71 days after the first administration.
- Changes from baseline in Triglyceride of Laboratory ExaminationTime frame: Within 71 days after the first administration.
- Changes from baseline in CHOL of Laboratory ExaminationTime frame: Within 71 days after the first administration.
- Changes from baseline in TP of Laboratory ExaminationTime frame: Within 71 days after the first administration.
- Changes from baseline in ALB of Laboratory ExaminationTime frame: Within 71 days after the first administration.
- Changes from baseline in UA of Laboratory ExaminationTime frame: Within 71 days after the first administration.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Henan Provincial Hospital for Infectious Diseases (Zhengzhou Sixth People's Hospital)
Zhengzhou, Henan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.